Tower Research Capital LLC (Trc) Janux Therapeutics, Inc. Transaction History
Tower Research Capital LLC (Trc)
- $5.8 Billion
- Q2 2024
A detailed history of Tower Research Capital LLC (Trc) transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 2,580 shares of JANX stock, worth $140,326. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,580
Previous 1,259
104.92%
Holding current value
$140,326
Previous $47,000
129.79%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding JANX
# of Institutions
160Shares Held
37.2MCall Options Held
70.4KPut Options Held
101K-
Ra Capital Management, L.P. Boston, MA9.17MShares$499 Million5.79% of portfolio
-
Orbimed Advisors LLC San Diego, CA2.98MShares$162 Million3.01% of portfolio
-
Black Rock Inc. New York, NY2.34MShares$127 Million0.0% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA2.33MShares$127 Million0.19% of portfolio
-
Janus Henderson Group PLC London, X01.8MShares$98 Million0.04% of portfolio
About Janux Therapeutics, Inc.
- Ticker JANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,663,000
- Market Cap $2.27B
- Description
- Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...